Male gender is an adverse prognostic factor in B-cell lymphoma patients treated with immunochemotherapy

Sari Riihijarvi, Minna Taskinen, Mats Jerkeman, Sirpa Leppa

Research output: Contribution to journalArticlepeer-review

56 Citations (SciVal)

Abstract

Male gender is an adverse prognostic factor in Hodgkin's lymphoma, but no such association has yet been established in non-Hodgkin lymphomas. Here, we have evaluated whether gender has prognostic impact on the survival of patients with B-cell non-Hodgkin lymphoma in the postrituximab era of lymphoma therapies. The study populations consisted of 217 diffuse large B-cell lymphoma (DLBCL) and 110 follicular lymphoma (FL) patients treated with immunochemotherapy. Hundred and sixty chemotherapy-treated DLBCL patients served as a control group. According to Kaplan-Meier analyses, female patients had a significantly better progression-free survival than men both in DLBCL (4 yr PFS 75% vs. 60%; P = 0.013) and in FL (4 yr PFS 68% vs. 52%, P = 0.036) patients treated with immunochemotherapy. In chemotherapy-treated DLBCL patients, no difference in survival between the genders was found. The results support the idea that women seem to respond better to rituximab.
Original languageEnglish
Pages (from-to)124-128
JournalEuropean Journal of Haematology
Volume86
Issue number2
DOIs
Publication statusPublished - 2011

Subject classification (UKÄ)

  • Hematology

Keywords

  • B-cell non-Hodgkin lymphoma
  • prognostic factors
  • gender
  • immunochemotherapy

Fingerprint

Dive into the research topics of 'Male gender is an adverse prognostic factor in B-cell lymphoma patients treated with immunochemotherapy'. Together they form a unique fingerprint.

Cite this